Chemotherapy News and Research

Latest Chemotherapy News and Research

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

A paper published online on June 13 in the Journal of Experimental Medicine identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)—a disease often associated with lack of response to chemotherapy and poor overall survival.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Policy issues related to dual-eligible patients, cancer medication coverage attract headlines

The Associated Press reports that seniors are facing Medicare cost barriers which sometimes lead them to not fill cancer drug prescriptions. Also, CQ HealthBeat reports that a special team within the Department of Health and Human Services is working on finding ways to save money and improve care for patients on both Medicare and Medicaid.

13 Jun 2011

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Sarcoma UK releases an inspiring film about the experiences of people living with a rare form of cancer of soft tissue and bone, as part of Sarcoma Awareness Week.

13 Jun 2011

Second course of treatment could cure head and neck cancer

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer.

13 Jun 2011

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Hundreds of surfers, cancer survivors and friends will gather together, with surfboards in hand, on La Jolla Shores Sunday, June 19 for an annual San Diego tradition: Survivor Beach. Attendees will place surfboards along the edge of the shore, nose-to-tail, from Scripps Pier down La Jolla Shores, with the goal of forming a record-breaking line of several hundred surfboards.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Hyperthermia prevents repair of tumor cells

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy.

10 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

Simple urine test could detect early stage cancers

Cancers of the gut, stomach and pancreas could be detected much sooner with a simple urine test, research suggests.

10 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

What starts as burning, numbness, pain, and/or tingling in the feet, or hands in some can turn into a debilitating condition. Peripheral Neuropathy (PN), one of the largest and most common neurodegenerative disorders, affects more than 20 million Americans of all races and ethnic backgrounds.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

New NCIN report: Poorer women more likely to die from breast cancer

Poorer women from deprived areas are less likely to survive breast cancer as they are diagnosed at a later stage which means the best available treatments won't be as effective according to a new report out today (Thursday) by the National Cancer Intelligence Network (NCIN).

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods.

8 Jun 2011

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy.

8 Jun 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Policy issues related to dual-eligible patients, cancer medication coverage attract headlines

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Second course of treatment could cure head and neck cancer

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Hyperthermia prevents repair of tumor cells

Ambit Biosciences raises $30 million through Series D-2 equity financing

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Simple urine test could detect early stage cancers

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

New NCIN report: Poorer women more likely to die from breast cancer

Patient enrollment complete in cilengitide Phase III study against glioblastoma

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in